Relationship between Vitamin C and Length of Hospital Stay for Covid-19 Patients with Comorbidities

Budiyanti Wiboworini, Amelya Augusthina Ayusari, Risalina Myrtha, Dwi Rahayu, Widardo Widardo, Yulia Lanti, Amalina Shabrina, Joko Sudarsono, Sutartinah Sri Handayani, Graciella Angelica Lucas

Abstract


Covid-19 patients with comorbidities, such as hypertension, diabetes, and respiratory diseases, have a higher risk for severe disease and mortality compared to patients without comorbidities. Some data shows that the administration of high dose vitamin C (1–2 g/day) can reduce the amount of the inflammatory mediators and shorten the length of hospital stay. This study aimed to determine the relationship between vitamin C administration and of length of hospital stay for Covid-19 patients with comorbidities. This study was a retrospective observational study on  consecutively sampled medical record data of UNS Hospital patients from July 2020 to January 2021. A total of 78 patient medical records were included of this study. The inclusion criteria were all medical records of patients who suffered from Covid-19 with comorbidities admitted to the hospital while the exclusion criteria were medical records of patients who did not get oral or intravenous vitamin C. The chi-square bivariate test was used to determine the relationship between the administration of vitamin C and the length of hospital stay for Covid-19 patients with comorbidities. Of the 78 subjects only 52 subjects were included in the statistical analysis. Medical records were divided into two groups: group 1, that consisted of medical records of patient who received more than 1,000 mg Vitamin C, and group 2, who received less than 1,000 mg Vitamin C. Results demonstrated that the administration of high dose vitamin C of more than 1,000 mg was not associated with the length of hospital stay (p=0.677). Thus, high dose of vitamin C is not associated with the length of hospital stay for Covid-19 patients with comorbidities, such as hypertension, diabetes, and respiratory disease. 


Keywords


Covid-19 patients with comorbidities, length of hospital stay, vitamin c

Full Text:

PDF

References


WHO. WHO Coronavirus Disease (COVID-19) Dashboard. 2021 [cited 30 January 2021].Available from: https://covid19.who.int.

Worldometers. Coronavirus Update (Live): 102,649,949 Cases and 2,216,723 Deaths from COVID-19 Virus Pandemic- Worldometer. 2021 [cited 30 January 2021] Available from: https://www.worldometers.info/coronavirus/#countries.

Gold MS, Sehayek D, Gabrielli S, Zhang X, McCusker C, Ben-Shoshan M. COVID-19 and comorbidities: a systematic review and meta-analysis. Postgrad Med. 2020;132(8):749–55.

Barazzoni R, Bischoff SC, Breda J, Wickramasinghe K, Krznaric Z, Nitzan D, et al. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection. Clin Nutr. 2020;39(6):1631–8.

McElvaney OJ, Hobbs BD, Qiao D, McElvaney OF, Moll M, McEvoy NL, et al. A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19. EBioMedicine. 2020;61:103026.

Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17(1):11–30.

Feyaerts AF, Luyten W. Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19?. Nutrition. 2020;79-80:110948.

Hemilä H, de Man AME. Vitamin C and COVID-19. Front Med (Lausanne). 2021;7:559811.

Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health. 2020;8:152.

Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? a meta-analysis. Diabetes Metab Syndr. 2020;14(4):535–45.

Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 diabetes and its impact on the immune system. Curr Diabetes Rev. 2020;16(5):442–9.

Zhong L, Wu Y, Gao J, Zhang J, Xie Q, He H, et al. Effects of hypertension on the outcomes of COVID-19: a multicentre retrospective cohort study. Ann Med. 2021;53(1):770–6.

Kang Y, Chen T, Mui D, Ferrari V, Jagasia D, Scherrer-Crosbie M, et al. Cardiovascular manifestations and treatment considerations in COVID-19. Heart. 2020;106(15):1132–41.




DOI: https://doi.org/10.15395/mkb.v54n1.2582

Article Metrics

Abstract view : 456 times
PDF - 411 times

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


 


Creative Commons License
MKB is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

 


View My Stats